New search | Conferencedetail
mail
Print view
 
 

4th Annual RAS Targeted Drug Development Summit

Evvnt Promotion / evvnt
-
26.09.2022 - 28.09.2022  Boston Marriott Burlington, One Burlington Mall Road, 01803 Burlington, Massachusetts, USA
Time: 8:30 AM - 6:00 PM
 
Conference themes
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.
Professional congress organizer (PCO)
Hanson Wade
 

Enquiries and Registration:

https://go.evvnt.com/1209735-2?pid=4832
Ms. Erin Thomas
 
Categories
General Medicine
Languages
English
Congress fees
USD 2599.00 - USD 5398.00
Participants expected
1000
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

OÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation newTreeEuropean Health Forum GasteinAlumni Club Medizinische Universität WienAGEM - Arbeitsgemeinschaft Ethnologie und MedizinÄrztekammer für WienHelix - Forschung & Beratung WienEuropean Public Health Association (EUPHA)